- Technology improves absorption of cannabidiol and bioactive compounds into the bloodstream
- It is now being used on all non-psychoactive cannabinoids and applied to edibles and health food products
- Patents have been awarded in the U.S. and Australia and are pending in 44 countries
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds. Its patent-protected technology has improved the ability of cannabinoid-products companies to deliver active ingredients to the body. With patents pending for tetrahydrocannabinol and other psychoactive cannabinoids (plus nicotine and non-steroidal anti-inflammatory drugs), the current technology is already being applied to the use of non-psychoactive cannabinoids. This innovation has yielded a high absorption hemp oil formula that is a source of omega and fatty acids.
The health benefits of the technology and the products it has enabled are many. Lexaria has developed a product that can reduce anxiety and stress, increase mental focus and boost physiological performance and recovery. It can reduce pain and inflammation as well, while acting as a vasodilator to improve circulation.
Improved bioabsorption and lowering the cost of edibles are not the only perks of LXRP’s technology. The boost to the product market, and to investors, is already being felt. Avoiding the need for inhalation or co-administering CBD with sugars or sweeteners, the technology accelerates intestinal absorption. This has enabled the development of protein energy bars for sports nutrition and chewable CBD tablets with no sugar. Hemp oil capsules in the TurboCBD™ brand (with American ginseng and Ginkgo biloba) and teas have also been developed.
Lexaria’s technology works by masking the taste of cannabinoids as they’re consumed. It also protects the bioactive ingredients as they pass through the stomach and increases bioabsorption in the intestines by 5–10X. This rate is about equal to that of inhalation, offering a viable alternative to smoking. Onset times are also reduced. Effects may be felt with 15–20 minutes, in contrast to up to two hours via other means.
The patent awarded to LXRP for the delivery of all non-psychoactive cannabinoids makes Lexaria the first company in the world to achieve this accomplishment. Awarded in the U.S. and Australia, it is now pending in 44 other countries while supporting research and development on cannabinoids across the industry. The company has filed 19 patent applications in the U.S. and internationally. It also expects additional patent acceptances and issuances in 2017 and over the coming years.
In fact, Lexaria has out-licensed the technology as part of its royalty business model, allowing third-party partners and distributors to profit and support their own developments. The numerous deals already signed include those in various state markets, including California, Colorado and Nevada, and a distribution agreement for CBD chewables in Japan and South Korea. Lexaria’s first royalty agreement was with a fast-growing startup, but current negotiations are with larger, more established enterprises. Lexaria is expanding its global reach and expects to continue seeing growth in business deals in broader industry sectors with more well-known consumer brands.
For more information, visit the company’s website at www.LexariaEnergy.com
Let us hear your thoughts: Lexaria Bioscience Corp. Message Board